Hormonal
Once-weekly mazdutide (3–6 mg) administered for 24 weeks produces robust, dose-dependent body weight reduction (up to 11.3%) and improves cardio-metabolic risk factors in Chinese overweight or obese adults.
For Chinese adults with obesity or overweight with related health issues, a once-weekly injection of mazdutide (up to 6 mg) for 24 weeks can lead to significant weight loss (up to 11%) and improved heart health markers. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically cause patients to stop treatment.
In summary, in Chinese overweight adults or adults with obesity, 24-week treatment with mazdutide up to 6 mg was safe and led to robust and clinically meaningful body weight reduction.
Why this rating
Phase 2 randomized controlled trial with placebo control, but limited by short duration (24 weeks) and single ethnic population.
Source
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Linong Ji et al. · Nature Communications · 2023
DOI 10.1038/s41467-023-44067-4
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →